Bavarian Nordic injects debt for GSK vaccines

Injection_Fotolia_230x150
By Mike Turner
21 Oct 2019

Denmark’s Bavarian Nordic will buy two commercial vaccines from GlaxoSmithKline for €796m, in a debt funded acquisition that will be refinanced next year in the equity market.

Biological sciences company Bavarian Nordic has agreed to buy rabies vaccine Rabipur and tick-borne encephalitis preventative Encepur from the UK drugs company. 

The acquisition includes a €301m upfront payment on the deal closing, which is expected to happen before the end of this year. Bavarian Nordic will then pay ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial